Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Angela Russell, Professor of Medicinal Chemistry in the Oxford Departments of Pharmacology and Chemistry, has been announced as one of the five recipients of the inaugural UK Rare Disease Scholar Award, presented by the Harrington Discovery Institute (HDI).

Professor Angela RussellThrough its UK charity, Fund for Cures UK, with Morgan Stanley GIFT Cures, HDI issued a call for proposals for cutting-edge research in rare diseases and rare variants of more common diseases. Around 350 million people worldwide have a rare disease, half of which are children. Of the 7,000 known rare diseases, only five percent have an approved treatment. Rare diseases represent one of the greatest unmet needs in global healthcare today.

In addition to her joint appointment between Pharmacology and Chemistry, Professor Russell is a member of the MDUK Oxford Neuromuscular Centre. She aims to develop new drugs for the treatment of Duchenne Muscular Dystrophy, a severe muscle disease with childhood onset.

Speaking of the launch of the Rare Disease Scholar Awards in the UK, Jonathan Stamler, President of the HDI, said, “In eight years we have built a strong portfolio of breakthrough science throughout the US and Canada, and we are excited to extend our reach to the United Kingdom. Together with our Scholars and their institutions, we are pleased to move one step closer to changing the rare disease landscape in a meaningful way.”

In response to the announcement of her award, Professor Russell commented, “I’m delighted to have been awarded a 2021 Harrington UK Rare Diseases Scholarship. The support and guidance the Harrington team provide will be instrumental to allow us to build on our collaborative work with Professor Dame Kay Davies’ group (DPAG), to develop a small molecule drug to increase utrophin levels at the muscle membrane to treat Duchenne muscular dystrophy patients.”

Similar stories

Consequences of Tau pathology on hippocampal pyramidal neurons and network activity in ageing mice

Pathological hyperphosphorylated forms of the microtubule-associated binding protein Tau (pTau) are commonly found in people with neurodegenerative diseases, including Alzheimer’s disease, Corticobasal degeneration, and Progressive supranuclear palsy.

Welcome to the 2022/23 academic year in Pharmacology!

At the start of this year, we have welcomed 23 new MSc in Pharmacology students, 13 new MSc(Res) and DPhil students and around a dozen additional project and visiting students from other Departments and other Universities. Some of these new starters joined existing staff, students and visitors in the Department for the first of a series of group photographs, to be taken every 6 months for our archives.

New Platt group paper explores links between Mycobacteria tuberculosis and Niemann-Pick Type C disease

Congratulations to Yuzhe Weng, a DPhil student in the Platt lab, who is first author on new paper published by the group in Nature Communications. Mycobacteria tuberculosis (Mtb), the causative agent of tuberculosis (TB), has the ability to invade, persist and replicate within host cells, which is key to its success as a pathogen. However, the mechanisms that underlie this strategy remain poorly defined.

PROFESSOR REBECCA SITSAPESAN 1959-2022

We were sad to learn that our dear colleague Rebecca has died just a few days before what would have been her 63rd birthday.

New high-resolution imaging provides clue to SARS-CoV-2 leap to humans

A new paper, published this week in the journal Science, highlights cutting-edge imaging techniques used by the group of Professor Ben Davis to investigate the binding of SARS-CoV-2 to human cells.

Dr Mehmood Khan joins Pharmacology as a Visiting Fellow

We are delighted to announce the appointment of Dr Mehmood Khan as a Visiting Fellow in the Department